Home
About Us
About Us
Our Team
News & Press
Why Ultra-Rare Diseases
Our Model
Therapy Tracker
Contact
Select Page
CACNA1A Upregulating ASO
Back to Therapy Pipeline
Submitting Organization:
The CACNA1A Foundation, Inc.
Treatment Modality:
Nucleic Acid/RNA/ASO
Development Stage:
Preclinical Phase - Preclinical Proof of Concept